Edgil Dianna, Williams Jason, Smith Peter, Kuritsky Joel
United States Agency for International Development (USAID), Washington, United States.
The Partnership for Supply Chain Management (PFSCM), Arlington, United States.
Afr J Lab Med. 2014 Sep 5;3(1):101. doi: 10.4102/ajlm.v3i1.101. eCollection 2014.
The Supply Chain Management System (SCMS) is a contract managed under the Partnership for Supply Chain Management (PFSCM) consortium by the United States Agency for International Development (USAID). SCMS procures commodities for programmes supported by the US President's Emergency Plan for AIDS Relief (PEPFAR). From 2005 to mid-2012, PEPFAR, through SCMS, spent approximately $384 million on non-pharmaceutical commodities. Of this, an estimated $90m was used to purchase flow cytometry technology, largely for flow cytometry platforms and reagents.
The purpose of this paper is to highlight the cost differences between low, medium and high utilisation rates of common CD4 testing instruments that have been procured though PEPFAR funding.
A scale of costs per test as a function of test volume through the machine was calculated for the two most common CD4 testing machines used in HIV programmes: Becton Dickinson (BD) FACSCount™ and BD FACSCalibur™. Instrument utilisation data collected at the facility level in three selected countries were then used to calculate the onsite cost-per-test experienced in each country.
Cost analyses indicated that a target of at least 40% utilisation for FACSCount™ and 15% utilisation for FACSCalibur™, respectively, closely approach maximal per-test cost efficiency. The average utilisation rate for CD4 testing instruments varies widely by country, level of laboratory and partner (0% - 68%).
Our analysis indicates that, because cost-per-test is related inversely to sample throughput, the underutilisation of flow cytometry machines is resulting in an increase in average cost-per-test for many instruments.
供应链管理系统(SCMS)是由美国国际开发署(USAID)根据供应链管理伙伴关系(PFSCM)财团管理的一项合同。SCMS为美国总统艾滋病紧急救援计划(PEPFAR)支持的项目采购商品。从2005年到2012年年中,PEPFAR通过SCMS在非药品商品上花费了约3.84亿美元。其中,估计9000万美元用于购买流式细胞术技术,主要用于流式细胞术平台和试剂。
本文的目的是突出通过PEPFAR资金采购的常见CD4检测仪器在低、中、高使用率之间的成本差异。
针对HIV项目中使用的两种最常见的CD4检测机器:贝克曼库尔特(BD)FACSCount™ 和BD FACSCalibur™,计算了每次检测成本随机器检测量变化的比例。然后,利用在三个选定国家的机构层面收集的仪器使用数据,计算每个国家的现场每次检测成本。
成本分析表明,FACSCount™ 的利用率至少达到40%,FACSCalibur™ 的利用率达到15%,分别接近每次检测的最大成本效率。CD4检测仪器的平均利用率因国家、实验室水平和合作伙伴的不同而有很大差异(0% - 68%)。
我们的分析表明,由于每次检测成本与样本通量成反比,流式细胞仪的未充分利用导致许多仪器的平均每次检测成本增加。